Levothyroxin
Phase 3Small molecule
Levothyroxin is one of 53 small molecule programs targeting Thyroid Cancer. It is currently in Phase 3.
2
Indications
14
Total Trials
2
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
65 competitors in Thyroid Cancer
#DrugCompanyPhaseTrials
1Lenvima
EisaiApproved
Retevmo
Eli LillyApproved
Vitrakvi
BayerApproved
Rozlytrek
RocheApproved
Caprelsa
GGenzyme, a Sanofi Company
Approved
Nexavar
BayerPhase 3
Mekinist
NovartisPhase 3
Gavreto
RRigel Pharmaceuticals
Approved
Farydak
SSecuraBio
Approved
Alimta
SShawn Eagle
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypothyroidism4 trials
Show 1 more trial
LIGHT Trial: Levothyroxine for Gestational Hypothyroidism in Recurrent Pregnancy Loss
Not yet recruiting·WWomen's Hospital School Of Medicine Zhejiang University·Phase 3·NCT06999278·200 enrolled
Screening1 trial
Final Height in Patients With CH Diagnosed by the Screening
Unknown status·—··NCT04734457·60 enrolled
Pregnant Women1 trial
Correlation Between Levothyroxine and Blood Th17/Treg in Pregnant Women With Normal-high TSH and Positive TPOAb
Terminated·—··NCT06527859·64 enrolled
Congenital Hypothyroidism1 trial
Pregnancy1 trial
Efficacy of Low Dose Levothyroxine During Pregnancy
Completed·—·Phase 3·NCT03391154·180 enrolled
6 more indications
Thyroid Dysfunction1 trial
The Prevalence and Risk Factors for Thyroid Dysfunction in Pregnant Women in Taiwan
Unknown status·—··NCT04936698·2,000 enrolled
Thyroid1 trial
Thyroid Cancer1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Levothyroxin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBerlin-Chemie AG Menarini Group